SelectQuote (SLQT) Q4 2026 earnings review
The Great Cash Flow Pivot: Shrinking Topline, Swelling Margins
SelectQuote's Q4 results and FY27 guidance cement a massive strategic shift: sacrificing growth to harvest cash. Q4 revenue fell 7% YoY, and FY27 guidance points to a severe 14% contraction at the midpoint. Yet, the strategy is working on the bottom line. Operating cash flow swung positively to $31.9M for FY26 and is guided to double to >$60M next year. Management is actively navigating a disrupted Medicare Advantage ecosystem by drastically shrinking the Senior segment volume, heavily relying on tech-driven cost savings ($30M target), and milking a maturing SelectRx pharmacy business.
🐂 Bull Case
The company has conclusively proven it can generate cash. The $44M YoY swing in FY26 OCF, paired with guidance to double it in FY27, gives SelectQuote essential balance sheet flexibility without needing near-term debt markets.
Despite flat membership, Healthcare Services exited FY26 with an annualized Adjusted EBITDA run-rate of nearly $50M. The new Kansas facility is structurally improving unit economics.
🐻 Bear Case
FY27 revenue guidance of $1.35B-$1.45B represents a 14% YoY decline. Cost-cutting can generate cash in the short term, but a shrinking distribution engine caps long-term equity upside.
SelectRx membership flatlined at 109K (up 1% YoY), and segment revenue actually fell 10% YoY in Q4. The transition from a hyper-growth engine to a cash-cow is happening abruptly.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for executing the cash-flow pivot precisely as promised. However, the aggressive FY27 revenue cut shows the core Medicare Advantage market remains highly distressed. We view the stock as a stabilized distressed asset rather than a growth story.
Key Themes
AI and Tech-Enabled Cost Extraction
A primary driver for the $60M OCF target is $30M+ in targeted annual cost savings for FY27. Management is heavily leaning on new AI implementations: 'Agent Sales Assist' to streamline workflows, 'Voice AI' for scalable enrollment support, and a custom 'Pharmacy Management System (PMS)'. By extracting human labor costs from the funnel, they are protecting margins despite lower carrier payouts.
SelectRx Growth Wall & Revenue Reversal
Healthcare Services revenue reversed course, falling 10% YoY in Q4 to $193.5M. Member counts flatlined entirely, going from 117K in Q3 to 109K in Q4 (a sequential drop, and only +1% YoY). While management previously flagged a strategic slowdown in member acquisition to focus on margins, the Q4 revenue contraction shows the segment is highly sensitive to PBM reimbursement pressure and drug pricing under the Inflation Reduction Act.
Senior Segment Contraction from Macro Disruption
The Medicare Advantage ecosystem is structurally broken at the moment. Carriers have slashed marketing budgets and tightened underwriting, heavily suppressing SelectQuote's volume. Q4 Approved MA policies fell 15% YoY to 72,180. Management's 26% margin in the Senior segment is impressive, but it is being achieved on a rapidly shrinking revenue base ($576M in FY26 vs $600M in FY25).
Life Segment: The Quiet Cash Cow
The Life segment continues to provide highly efficient, stable cash flow. Q4 Adjusted EBITDA spiked 41% YoY to $9.8M, yielding a stellar 20% margin. Full-year premiums grew 5% to $185M, driven by steady demand in Final Expense. This segment acts as a vital counterweight to the volatility in the Senior Medicare Advantage market.
Other KPIs
Stable. Up slightly (+5%) from $837 in 25Q4, but down 1% for the full fiscal year ($873 vs $884). This stability indicates that despite the chaotic carrier environment, the quality and persistency of the policies SelectQuote actually writes remain intact.
Decelerating efficiency on a unit basis. This metric increased 13% YoY for the TTM period, largely driven by the cost of goods sold in the pharmacy business scaling up. While overall corporate OCF is positive, the absolute cost per policy acquired continues to inflate.
Guidance
Decelerating. At the $1.40B midpoint, this implies a massive 14% YoY contraction from FY26's $1.618B. Management is intentionally stepping away from low-margin volume, but an end-market decline of this magnitude signifies extreme distress in carrier partner marketing budgets.
Stable. The $102.5M midpoint is a slight 6% decline from FY26 ($109.1M). Protecting EBITDA while shedding $200M+ in revenue requires flawless execution of the promised $30M in tech-driven operating efficiencies.
Accelerating. This is the lynchpin of the entire investment thesis. Doubling OCF from $31.9M to >$60M shifts the company out of restructuring danger and opens the door for deleveraging or stock buybacks to remedy the previously noted 'dislocated valuation'.
Key Questions
SelectRx Member Churn
SelectRx members fell sequentially from 117K in Q3 to 109K in Q4. Was this an intentional shedding of unprofitable cohorts, or is customer churn accelerating due to PBM changes?
Floor for Senior Revenue
With FY27 revenue guided down 14%, at what point do fixed costs in the Senior distribution network become stranded? Where is the absolute bottom for MA policy volumes?
Delisting / Strategic Actions
In Q3, management explicitly stated they would take 'all necessary action' to remedy the stock's valuation and maintain NYSE listing. Now that strong OCF is confirmed for FY27, what is the timeline for aggressive capital actions (buybacks, M&A)?